152 related articles for article (PubMed ID: 31791642)
1. Corrigendum to "Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer" [Eur. J. Med. Chem. 163 (2019) 787-803].
Wang C; Wang B; Hou S; Xue L; Kang Z; Du J; Li Y; Liu X; Wang Q; Zhang C
Eur J Med Chem; 2020 Jan; 186():111907. PubMed ID: 31791642
[No Abstract] [Full Text] [Related]
2. Discovery of novel nonsteroidal VDR agonists with novel diarylmethane skeleton for the treatment of breast cancer.
Wang C; Wang B; Hou S; Xue L; Kang Z; Du J; Li Y; Liu X; Wang Q; Zhang C
Eur J Med Chem; 2019 Feb; 163():787-803. PubMed ID: 30579121
[TBL] [Abstract][Full Text] [Related]
3. Corrigendum to 'Synthesis and discovery of a drug candidate for treatment of idiopathic pulmonary fibrosis through inhibition of TGF-b1 pathway' [Eur. J. Med. Chem. 157 (2018) 229-247].
Li X; Lu C; Liu S; Liu S; Su C; Xiao T; Bi Z; Sheng P; Huang M; Liu X; Wei Y; Zhao L; Miao S; Mao J; Huang K; Gao S; Liu N; Qi M; Liu T; Qin S; Wei L; Sun T; Ning W; Yang G; Zhou H; Yang C
Eur J Med Chem; 2019 Feb; 163():403. PubMed ID: 30530191
[No Abstract] [Full Text] [Related]
4. Corrigendum to "Discovery of orally active anticancer candidate CFI-400945 derived from biologically promising spirooxindoles: Success and challenges" [Eur. J. Med. Chem. 95 (2015) 35-40].
Yu B; Yu Z; Qi PP; Yu DQ; Liu HM
Eur J Med Chem; 2016 Nov; 124():248. PubMed ID: 27592393
[No Abstract] [Full Text] [Related]
5. Corrigendum to "Discovery of novel BCR-ABL PROTACs based on the cereblon E3 ligase design, synthesis, and biological evaluation" [Eur. J. Med. Chem. 223 (2021) 11-05 113645].
Liu H; Ding X; Liu L; Mi Q; Zhao Q; Shao Y; Ren C; Chen J; Kong Y; Qiu X; Elvassore N; Yang X; Yin Q; Jiang B
Eur J Med Chem; 2023 Apr; 252():115295. PubMed ID: 36989810
[No Abstract] [Full Text] [Related]
6. Corrigendum to "Discovery of new azoles with potent activity against Candida spp. and Candida albicans biofilms through virtual screening" [Eur. J. Med. Chem. 179 (2019) 634-648].
Sari S; Kart D; Öztürk N; Kaynak FB; Gencel M; Taşkor G; Karakurt A; Saraç S; Eşsiz Ş; Dalkara S
Eur J Med Chem; 2020 Mar; 190():112130. PubMed ID: 32074493
[No Abstract] [Full Text] [Related]
7. Corrigendum to "Design and synthesis of novel artemisinin hybrids with potent activities against human colorectal cancer cells in vitro and in vivo" [Eur. J. Med. Chem. 182 (2019) 111665].
Wang LL; Kong L; Liu H; Zhang Y; Zhang L; Liu X; Yuan F; Li Y; Zuo Z
Eur J Med Chem; 2020 May; 194():112256. PubMed ID: 32220686
[No Abstract] [Full Text] [Related]
8. Corrigendum to "Synthesis and cytotoxic activity of novel A-ring cleaved ursolic acid derivatives in human non-small cell lung cancer cells" [Eur. J. Med. Chem. 123 (2016) 317-331].
Mendes VIS; Bartholomeusz GA; Ayres M; Gandhi V; Salvador JAR
Eur J Med Chem; 2016 Nov; 124():1004-1005. PubMed ID: 27783971
[No Abstract] [Full Text] [Related]
9. Corrigendum to "Discovery of a potent, selective and cell active inhibitor of m6A demethylase ALKBH5" [Eur. J. Med. Chem. 238 (2022) 114446].
Fang Z; Mu B; Liu Y; Guo N; Xiong L; Guo Y; Xia A; Zhang R; Zhang H; Yao R; Fan Y; Li L; Yang S; Xiang R
Eur J Med Chem; 2023 Jul; 255():115368. PubMed ID: 37119665
[No Abstract] [Full Text] [Related]
10. Corrigendum to "Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer" [Eur. J. Med. Chem. 259 (2023) 115703/5].
Fang B; Lai Y; Yan H; Ma Y; Ni Z; Zhu Q; Zhang J; Ye Y; Wang M; Wang P; Wang Y; Zhang S; Hui M; Wang D; Zhao Y; Li X; Wang K; Liu Z
Eur J Med Chem; 2024 Mar; 268():116230. PubMed ID: 38368135
[No Abstract] [Full Text] [Related]
11. Corrigendum to "Identification of novel β-lactams and pyrrolidinone derivatives as selective Histamine-3 receptor (H3R) modulators as possible anti-obesity agents" [Eur. J. Med. Chem. 152 (2018) 148-159].
Ghoshal A; Kumar A; Yugandhar D; Sona C; Kuriakose S; Nagesh K; Rashid M; Singh SK; Wahajuddin M; Yadav PN; Srivastava AK
Eur J Med Chem; 2018 Aug; 156():628-630. PubMed ID: 30031973
[No Abstract] [Full Text] [Related]
12. Corrigendum to "Matrix metalloproteinase-9 (MMP-9) and its inhibitors in cancer: A minireview" [Eur. J. Med. Chem. 194 (2020) 112260].
Mondal S; Adhikari N; Banerjee S; Amin SA; Jha T
Eur J Med Chem; 2020 Nov; 205():112642. PubMed ID: 32750565
[No Abstract] [Full Text] [Related]
13. Corrigendum to <'Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d] pyrimidine analogues as novel CHK1 inhibitors' [Eur. J. Med. Chem. 151 (2018) 836-848].
Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J
Eur J Med Chem; 2019 Jul; 173():184. PubMed ID: 31003059
[No Abstract] [Full Text] [Related]
14. Corrigendum to "Tetrahydropyridin-4-ylpicolinoylglycines as novel and orally active prolyl hydroxylase 2 (PHD2) inhibitors for the treatment of renal anemia" [Eur. J. Med. Chem. 238 (2022) 114479].
Su K; Li Z; Zhang L; Fang S; Mao M; Sun Z; Zhang X
Eur J Med Chem; 2023 Nov; 259():115692. PubMed ID: 37550158
[No Abstract] [Full Text] [Related]
15. Corrigendum to "Design, synthesis and evaluation of novel thienopyrimidine-based agents bearing diaryl urea functionality as potential inhibitors of angiogenesis" [Eur. J. Med. Chem 209 (2021) 112942].
Faraji A; Oghabi Bakhshaiesh T; Hasanvand Z; Motahari R; Nazeri E; Boshagh MA; Firoozpour L; Mehrabi H; Khalaj A; Esmaeili R; Foroumadi A
Eur J Med Chem; 2021 Mar; 214():113228. PubMed ID: 33550180
[No Abstract] [Full Text] [Related]
16. Corrigendum to "Design, synthesis, and biological evaluation of novel tetrahydroprotoberberine derivatives to reduce SREBPs expression for the treatment of hyperlipidemia" [Eur. J. Med. Chem. 221 (2021) 113522].
Ge H; Zhang W; Yuan K; Xue H; Cheng H; Chen W; Xie Y; Zhang J; Xu X; Yang P
Eur J Med Chem; 2022 Jan; 228():114041. PubMed ID: 34902733
[No Abstract] [Full Text] [Related]
17. Corrigendum to"Isoindoline scaffold-based dual inhibitors of HDAC6 and HSP90 suppressing the growth of lung cancer in vitro and in vivo"[Eur. J. Med. Chem. 190 (2020 Mar 15) 112086].
Ojha R; Nepali K; Chen CH; Chuang KH; Wu TY; Lin TE; Hsu KC; Chao MW; Lai MJ; Lin MH; Huang HL; Chang CD; Pan SL; Chen MC; Liou JP
Eur J Med Chem; 2020 Sep; 201():112404. PubMed ID: 32526554
[No Abstract] [Full Text] [Related]
18. Corrigendum to "Synthesis of a series of novel dihydroartemisinin monomers and dimers containing chalcone as a linker and their anticancer activity" [Eur. J. Med. Chem. 122 (2016) 232-246].
Gaura R; Pathania AS; Malik FA; Bhakuni RS; Verma RK
Eur J Med Chem; 2022 May; 235():114277. PubMed ID: 35344906
[No Abstract] [Full Text] [Related]
19. Corrigendum to"An insight into the medicinal perspective of synthetic analogs of indole: A review" [Eur. J. Med. Chem. 180 (2019) 562-612 11516].
Thanikachalam PV; Maurya RK; Garg V; Monga V
Eur J Med Chem; 2019 Dec; 183():111680. PubMed ID: 31520927
[No Abstract] [Full Text] [Related]
20. Corrigendum to "Optimization of physicochemical properties for 4-Anilinoquinazoline inhibitors of trypanosome proliferation" [Eur. J. Med. Chem. 141 (2017) 446-459].
Woodring JL; Bachovchin KA; Brady KG; Gallerstein MF; Erath J; Tanghe S; Leed SE; Rodriguez A; Mensa-Wilmot K; Sciotti RJ; Pollastri MP
Eur J Med Chem; 2018 May; 152():515. PubMed ID: 29754075
[No Abstract] [Full Text] [Related]
[Next] [New Search]